Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Total Current Liabilities (2021 - 2025)

Historic Total Current Liabilities for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $1.5 million.

  • InMed Pharmaceuticals' Total Current Liabilities fell 1736.24% to $1.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.5 million, marking a year-over-year decrease of 1736.24%. This contributed to the annual value of $1.8 million for FY2025, which is 669.53% down from last year.
  • As of Q4 2025, InMed Pharmaceuticals' Total Current Liabilities stood at $1.5 million, which was down 1736.24% from $1.6 million recorded in Q3 2025.
  • InMed Pharmaceuticals' Total Current Liabilities' 5-year high stood at $4.6 million during Q4 2021, with a 5-year trough of $1.3 million in Q3 2023.
  • For the 5-year period, InMed Pharmaceuticals' Total Current Liabilities averaged around $2.2 million, with its median value being $1.9 million (2021).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 7031.92% in 2022, then crashed by 5919.48% in 2023.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Total Current Liabilities stood at $4.6 million in 2021, then crashed by 48.01% to $2.4 million in 2022, then plummeted by 30.0% to $1.7 million in 2023, then grew by 6.57% to $1.8 million in 2024, then dropped by 17.36% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q4 2025, $1.6 million for Q3 2025, and $1.8 million during Q2 2025.